The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Understanding causes of racial/ethnic survival disparity in 47,178 patients with colorectal cancer: A quantitative evaluation of molecular, socioeconomic, and clinical covariates.
 
Mahmoud M.G. Yousef
No Relationships to Disclose
 
Abdelrahman M.G. Yousef
No Relationships to Disclose
 
Mohammad Mahdi Fanaeian
No Relationships to Disclose
 
Saikat Chowdhury
Patents, Royalties, Other Intellectual Property - Sarkar, R.R., Chowdhury, S. (2021) Method to predict pathological grade and to identify drug targets against glioma tumor. US17/154,379 filed on July 29, 2021. Patent Pending; Sarkar, R.R., Ganguli, P., Chowdhury, S. (2020) Identification of minimal combinations of molecules that act as probable immunostimulators against Leishmaniasis. US15/776,008 filed on January 16, 2020. Patent Pending
 
Mark Knafl
No Relationships to Disclose
 
Mohammad Zeineddine
No Relationships to Disclose
 
Kristin Alfaro
Consulting or Advisory Role - Abbvie; SDP Oncology
 
Abhineet Uppal
Honoraria - Bayer
 
Ryan Sun
Consulting or Advisory Role - Boehringer Ingelheim; Boehringer Ingelheim
Research Funding - Sanofi
 
Wenyi Wang
No Relationships to Disclose
 
Kanwal Pratap Singh Raghav
Honoraria - Bayer; Daiichi Sankyo/Astra Zeneca; Eisai; Merck; Seagen
Consulting or Advisory Role - Bayer; Daiichi Sankyo/Astra Zeneca; Eisai; Merck; Seagen
Research Funding - Abbvie (Inst); Bayer (Inst); Daiichi Sankyo/Astra Zeneca (Inst); Eisai (Inst); Guardant Health (Inst); HiberCell (Inst); Innovent Biologics (Inst); Janssen (Inst); Merck Serono (Inst); Roche/Genentech (Inst); UCB (Inst); Xencor (Inst)
 
Jason Willis
Honoraria - Bayer; Cor2Ed
 
Scott Kopetz
Stock and Other Ownership Interests - Frontier Medicines; Iylon; Lutris; Navire; Xilis
Consulting or Advisory Role - Abbvie; Accademia Nazionale Di Medicina (ACCMED); Amal Therapeutics; Amgen; AstraZeneca/MedImmune; AVEO; Bayer Health; Bicara Therapeutics; Black Diamond Therapeutics; Boehringer Ingelheim; Bristol-Myers Squibb/Medarex; Cardiff Oncology; Carina Biotech; CureTeq; EMD Serono; Endeavor BioMedicines; Flame Biosciences; Foundation Medicine; Frontier Medicines; Genentech; Genomic Health; Gilead Sciences; GlaxoSmithKline; HalioDx; Harbinger Oncology, Inc; Holy Stone Healthcare; Inivata; Ipsen; Iylon; Jacobio; Jazz Pharmaceuticals; Johnson & Johnson/Janssen; Lilly; Lutris; Merck; Mirati Therapeutics; NeoGenomics Laboratories; Novartis; Numab; Ono Pharmaceutical; Pfizer; Redx Pharma; Repare Therapeutics; Replimune; Roche; Sanofi; Servier; Tachyon Therapeutics; Taiho Pharmaceutical; Takeda; Tempus; Xilis; Zentalis
Research Funding - Amgen; Array BioPharma; Biocartis; Daiichi Sankyo; EMD Serono; Genentech/Roche; Guardant Health; Lilly; MedImmune; Novartis; Sanofi
 
John Paul Y.C. Shen
Stock and Other Ownership Interests - Agios; Syndax; Syndax
Consulting or Advisory Role - Engine Biosciences
Research Funding - BostonGene; Celsius Therapeutics; Celsius Therapeutics